Systemic immune correlates of long-term survival after Delta-24-RGD based on the Therapeutic Adenovirus for Recurrent Glioblastoma Effect Trial (TARGET)

Immunological fitness, assessed by an anti-adenoviral specific antibody response and higher levels of activated CD8+ NKT-like cells after Delta-24-RGD treatment, may have utility as an early surrogate of a robust systemic immune response that correlates with long-term survival.